[Comparison of the efficacy and safety of compound carraghenates cream and compound carraghenates suppository in the treatment of mixed hemorrhoids].
OBJECTIVE
To evaluate and compare the efficacy and safety of titanoreine cream with compound carraghenates suppository in the treatment of mixed hemorrhoids.


METHODS
Two hundred and fifty-two patients with mixed hemorrhoids were enrolled in this randomized,open, multicentral trial. Patients applied titanoreine cream (study group, n=133) or compound carraghenates suppository (control group, n=119). The symptomatic relief including pain,bleeding and edema was evaluated by scoring system at 30 minutes, 3 hours, 6 hours, 1 day, 2 days, 3 days, 4 days, 6 days after administration.


RESULTS
Symptoms were significantly improved in both groups (87.3%, 94.8%, respectively) excepting symptom of pain relief, but there was no significant difference between two groups (P > 0.05). The pain scores were lower at every observing point in the study group than those in the control group (P< 0.05). The proportions of the patients with pain relief and all symptoms relief were both higher in the study group than that in the control group at 30 min, 3 h after drug used (both P< 0.01). No side effect was found during the triad.


CONCLUSIONS
Titanoreine cream has predominance of relieving pain and response time compared with compound carraghenates suppository, but other effects on mixed hemorrhoid are similar between the two groups.
Yang
Xiao-dong
XD
Department of Gastrointestinal Surgery, Shenzhen People's Hospital, Shenzhen 518020, China. PiPirang@sina.com.cn
Wang
Jian-ping
JP
Kang
Jia-bao
JB
Chen
Zhao-wen
ZW
Cao
Jin-duo
JD
Yao
Li-qing
LQ
Yang
Xin-qing
XQ
D000328:Adult; D002351:Carrageenan / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006484:Hemorrhoids / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009824:Ointments / Q000627:therapeutic use; D012449:Safety; D013488:Suppositories / Q000627:therapeutic use; D014025:Titanium / Q000009:adverse effects / Q000627:therapeutic use*; D015034:Zinc Oxide / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D009824:Ointments; D013488:Suppositories; C042404:titanoreine; D002351:Carrageenan; D014025:Titanium; D015034:Zinc Oxide